Table 1. Summary of dose optimization MRI data by dose group.

MRI Index	Dose	Baseline	Endpoint	Paired t-test
		(t = 4 wk)	(t = 8 wk)	p value
Scar mass (g)	Placebo	8.3±0.8	8.5±1.3	ns
	15 mill CSps	8.8±1.9	8.6±2.9	ns
	45 mill CSps	7.9±2.9	7.0±3.1	0.023
	150mill CSps	10.0±2.2	8.4±1.3	ns
Scar size (% of LV)	Placebo	11.6±1.7	12.3±2.9	ns
	15 mill CSps	12.0±3.9	11.0±3.8	ns
	45 mill CSps	12.0±3.6	10.1±3.5	<0.001
	150mill CSps	13.4±1.8	10.3±1.8	0.043
Viable myocardium (g)	Placebo	63.6±5.3	60.9±8.0	ns
	15 mill CSps	70.4±12.2	72.2±6.3	ns
	45 mill CSps	58.0±5.3	62.4±5.9	ns
	150mill CSps	64.3±7.3	74.8±11.8	0.038
LV mass (g)	Placebo	71.9±4.7	69.4±7.2	ns
	15 mill CSps	79.2±11.4	80.8±5.9	ns
	45 mill CSps	65.9±7.8	69.3±8.8	ns
	150mill CSps	74.3±8.9	83.2±12.2	0.039
LVEF (%)	Placebo	47.6±2.4	42.9±2.4	0.002
	15 mill CSps	43.7±5.8	41.7±5.6	0.024
	45 mill CSps	45.2±3.1	44.0±4.8	ns
	150mill CSps	47.5±3.0	48.6±1.8	ns
EDV (ml)	Placebo	71.1±10.2	79.6±10.5	ns
	15 mill CSps	81.2±11.0	88.6±13.7	ns
	45 mill CSps	65.8±14.4	74.1±12.6	ns
	150mill CSps	73.2±5.8	79.6±11.4	ns
ESV (ml)	Placebo	37.4±6.0	45.6±7.7	0.015
	15 mill CSps	45.7±7.5	51.3±6.8	ns
	45 mill CSps	36.2±8.9	41.7±9.0	ns
	150mill CSps	38.4±1.8	40.9±5.4	ns
Body Weight Gain (kg)	Placebo	n/a	6.6±1.9	ns (ANOVA & Ind t-test)
	15 mill CSps	n/a	8.1±3.0
	45 mill CSps	n/a	6.5±2.9
	150mill CSps	n/a	8.1±2.2
HR during MRI (bpm)	Placebo	n/a	119±10	ns (ANOVA & Ind t-test)
	15 mill CSps	n/a	109±17
	45 mill CSps	n/a	111±15
	150mill CSps	n/a	108±13